Apellis Pharmaceuticals (NASDAQ:APLS) Target Lowered by Citigroup Inc to $54.00

0
27
Asset Protection Stock Market Wall Street Secure Your Wealth 3d Illustration

Apellis Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Apellis Pharmaceuticals stock Target Lowered by   Citigroup Inc on 6/30/2020. In a note to investors, the firm issued a new target price of $54.00. The analysts previously had $56.00 target price. Citigroup Inc’s price target would indicate a potential upside of 75.50% from the stock’s previous close.

Shares of Apellis Pharmaceuticals traded up $0.94 on Tuesday, reaching $31.71. 273740 shares of the stock traded hands, compared to its average volume of 925626. Shares of were trading at $31.71 on Tuesday. The firm’s 50 day moving average is $$32.89 and its 200 day moving average is $31.36.Apellis Pharmaceuticals  has a 12 month low of $30.37 and a 12 month high of $45.04. While on yearly highs and lows, Apellis Pharmaceuticals today has traded high as $32.08 and has touched $30.37 on the downward trend.

Apellis Pharmaceuticals Earnings and What to expect: 

Apellis Pharmaceuticals last issued its quarterly earnings data on April 29th, 2020. The reported ($2.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.38) by $0.91. Apellis Pharmaceuticals has generated ($4.64) earnings per share over the last year. Apellis Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, July 29th, 2020 based off prior year’s report dates.

Earnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($6.27) to ($5.63) per share. The P/E ratio of Apellis Pharmaceuticals is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Apellis Pharmaceuticals is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Apellis Pharmaceuticals has a P/B Ratio of 68.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 9.50%
  • On 6/15/2020 Director Alec Machiels Sell 2,500 at average share price of $30.21 which equates to $75,525.00 in money value.
  • On 6/15/2020 CEO Cedric Francois Sell 5,000 at average price of  $30.21 with total value of : Not Data Available
  • On 11/15/2019 CEO Cedric Francois Sell 5,000 at average price of  $27.82 with total value of : $139,100.00
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Apellis Pharmaceuticals

  • 6/16/2020 – Apellis Pharmaceuticals is now covered by analysts at BTIG Research. They set a “neutral” rating on the stock.
  • 6/12/2020 – Apellis Pharmaceuticals had its “buy” rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $62.00 price target on the stock.
  • 6/8/2020 – Apellis Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $54.00 to $56.00. They now have an “overweight” rating on the stock.
  • 6/5/2020 – Apellis Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • See More Analyst Rating at: RATING

Other rating updates by Citigroup Inc: 

  • 6/30/2020 – Intercept Pharmaceuticals was upgraded by analysts at Citigroup Inc from a “neutral” rating to a “buy” rating.
  • 6/30/2020 – DISH Network had its price target raised by analysts at Citigroup Inc from $35.00 to $39.00. They now have a “buy” rating on the stock.
  • 6/30/2020 – Extra Space Storage had its price target raised by analysts at Citigroup Inc from $100.00 to $105.00. They now have a “buy” rating on the stock.
  • 6/30/2020 – Harpoon Therapeutics had its price target raised by analysts at Citigroup Inc from $23.00 to $24.00. They now have a “buy” rating on the stock.
  • See More Analyst Rating at: RATING

Apellis Pharmaceuticals (NASDAQ:APLS) Moving Average Technical Analysis

5 day Moving Average is $$30.94 And 5 day price change is -$0.97 (-2.98%)  with average volume for 5 day average is 727,593. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $31.65 and 20 day price change is -$2.15 (-6.38%) and average 20 day moving volume is 954,138. 50 day moving average is $32.89  and 50 day price change is -$4.22 ( -11.80%)  and with average volume for 50 days is : 937,155. 200 day moving average is $31.36  and 200 day price change is $4.53 (16.78%)  and with average volume for 200 days is : 1,068,324.

See More Analyst Rating at: RATING